Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne

Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 Applied in a Split-face (Left/Right) Topical Design in Adults With Moderate to Severe Acne

An exploratory Phase 2, single, centre, prospective, randomized, placebo-controlled, double-blinded, split-pace (left/right) design trial to evaluate the efficacy and tolerability of LEO 43204 in adults with moderate to severe acne.

Study Overview

• Status: Completed
• Conditions: Acne Vulgaris
• Intervention / Treatment: Drug: Placebo; Drug: LEO43204

• Study Type: Interventional
• Enrollment (Actual): 59
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • Lomita, California, United States, 90717
      • Torrance Clinical Research Institute Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 31 years (Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Subjects should be diagnosed with acne vulgaris of the face
• Fitzpatrick skin types I-III (due to lack of safety data for the investigational product in darker skin types)
• Disease severity and total lesion count should be similar in both TAs
• Disease severity grade as moderate to severe according to the investigator's global assessment (grade 3-4)
• Age 18 to 35 years incl.
• Male or female
• Female Subjects must be of either non-childbearing potential or child-bearing potential with a confirmed negative pregnancy test

Exclusion Criteria:

• Subjects with nodulocystic acne, acne conglobata, acne fulminans, secondary acne (e.g. chlor-acne, drug-induced acne)
• Subjects with previous history of keloid formation or post-inflammatory hyperpigmentation
• Systemic retinoids within 12 month or systemic antibiotics within 1 month before Day 1
• Topical retinoids within 3 months before Day 1 or other topical treatments and/or medicated products and cosmetics that in the opinion of the investigator may influence the subjects acne vulgaris (including soaps containing antibacterial agents such as benzoyl peroxide, keratinolytic agents such as salicylic acid, skin fresheners/astringents or aftershave products) within 1 month before Day 1

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Vehicle; Placebo	Drug: Placebo
Experimental: LEO43204 0,018%; Experimental drug	Drug: LEO43204

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total Lesion Count (Inflammatory and Non-inflammatory)	Total lesion count (inflammatory and non-inflammatory) in acne lesion areas.	At Week 12 (Day 84)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Inflammatory Lesion Count	Count of inflammatory lesions in acne lesion areas	At Week 12 (Day 84)
Non-inflammatory Lesion Count	Count of non-inflammatory lesions in acne lesion areas	At Week 12 (Day 84)
Number of Participants Stratified by Investigator's Global Assessment (IGA) of the Treatment Area	The IGA score was determined according to the 5 point scale below. 0=Clear skin with no inflammatory and non-inflammatory lesions; Almost clear; rare non-inflammatory lesions with no more than one small inflammatory lesion; Mild severity; greater than Grade 1; some non-inflammatory lesions with no more than a few inflammatory lesions (papules/pustules only, no nodular lesions); Moderate severity; greater than Grade 2; up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesions; Severe; greater than Grade 3; up to many non-inflammatory and inflammatory lesions, but no more than a few nodular lesions	At Week 12 (Day 84)
Composite Local Skin Response (LSR) Score at All Visits	The Local Skin Responses consists of the following 6 components: erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, erosion/ulceration. Each individual LSR component is given a numeric grade of severity from 0-4. Grade 0 being no presence and Grade 4 being the highest grade of severity. The composite LSR score (0-24) is the sum of the scores graded from 0 to 4 on all six individual LSR categories. Please see following outcome measure descriptions on the grading scale for the individual components: Erosion/ulceration: 6. Secondary outcome measure; Crusting: 7. Secondary outcome measure.; Erythema: 8. Secondary outcome measure.; Flaking/scaling: 9. Secondary outcome measure.; Swelling: 10. Secondary outcome measure.; Vesiculation/pustulation: 11. Secondary outcome measure.	At baseline (Day 1), Day 2, Day 3, Day 4, Day 8, Week 2, Week 4, Week 8 and Week 12
Participant's Component LSR Score: Erosion/Ulceration	The Erosion/Ulceration score was determined according to the 5 point scale below. 0=not present; Lesion specific erosion; Erosion extending beyond individual lesions; Erosion >50%; Black eschar or ulceration	At Day 1, Day 2, Day 3, Day 4, Day 8, Week 2, Week 4, Week 8 and Week 12
Participant's Component LSR Score: Crusting	The crusting score was determined according to the 5 point scale below. 0=not present; isolated crusting; Crusting<50%; Crusting>50%; Crusting extending outside treatment area	At Day 1, Day 2, Day 3, Day 4, Day 8, Week 2, Week 4, Week 8 and Week 12
Participant's Component LSR Score: Erythema	The erythema score was determined according to the 5 point scale below. Erythema 0=not present; slightly pink <50%; Pink or light red >50%; Red,restricted to treatment area; Red extending outside treatment area	At Day 1, Day 2, Day 3, Day 4, Day 8, Week 2, Week 4, Week 8 and Week 12
Participant's Component LSR Score: Flaking/Scaling	The flaking/scaling score was determined according to the 5 point scale below. 0=not present; Isolated scale, specific to lesion; Scale<50%; Scale>50%; Scaling extending outside treatment area	At Day 1, Day 2, Day 3, Day 4, Day 8, Week 2, Week 4, Week 8 and Week 12
Participant's Component LSR Score: Swelling	The swelling score was determined according to the 5 point scale below. 0=Not present; Slight, lesion specific oedema; Palpable oedema extending beyond individual lesions; Confluent and/or visible oedema; Marked swelling extending outside treatment area	At Day 1, Day 2, Day 3, Day 4, Day 8, Week 2, Week 4, Week 8 and Week 12
Participant's Component LSR Score: Vesiculation/Pustulation	The vesiculation/postulation score was determined according to the 5 point scale below. 0=not present; vesicles only; Transudate or pustulates with or without vesicles <50%; Transudate or pustulates, with or without vesicles >50%; Transudate or pustulates, with or without vesicles extending outside treatment area 4=Marked swelling extending outside treatment area	At Day 1, Day 2, Day 3, Day 4, Day 8, Week 2, Week 4, Week 8 and Week 12
Number of Participants With Occurrence of Unacceptable LSR Scores or Unacceptable Safety and Tolerability Events at All Visits	Unacceptable LSRs, safety and tolerability in an individual participant were defined as: Clinically relevant signs or symptoms that in the opinion of the investigator were deemed unacceptable.; Occurrence of LSRs as specified below: One of the following; Grade 4 crusting; Grade 4 erosion/ulceration; Grade 4 vesiculation/pustulation extending significantly outside treatment areas Two of the following; Grade 4 erythema; Grade 3 crusting; Grade 4 swelling extending significantly outside treatment areas; Grade 3 erosion/ulceration; Grade 3 vesiculation/pustulation	At Day 1, Day 2, Day 3, Day 4, Day 8, Week 2, Week 4, Week 8 and Week 12

Collaborators and Investigators

• Sponsor: LEO Pharma
• Investigators: Principal Investigator: Hala Koudsi, MD, Torrance Clinical Research Institute Inc.

Publications and helpful links

Helpful Links

• Clinical Trials at LEO Pharma

Study record dates

Study Major Dates

• Study Start: June 1, 2016
• Primary Completion (Actual): April 1, 2017
• Study Completion (Actual): April 1, 2017

Study Registration Dates

• First Submitted: October 13, 2015
• First Submitted That Met QC Criteria: October 14, 2015
• First Posted (Estimated): October 15, 2015

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 21, 2025
• Last Verified: February 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Acneiform Eruptions; Sebaceous Gland Diseases; Acne Vulgaris
• Other Study ID Numbers: EXP-1223

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO